ArticleInflammopharmacology2026
Imeglimin confers protection against intestinal ischemia/reperfusion injury in rats through AMPK-dependent inhibition of NF-κB/NLRP3 inflammasome signaling and mitigation of oxidative stress and apoptosis.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimIntestinal ischemia/reperfusion (I/R) injury is a critical condition characterized by oxidative stress, inflammation, and apoptosis, leading to significant tissue damage. Imeglimin (IMEG), a novel antidiabetic agent, has recently shown cytoprotective effects through modulation of mitochondrial function, oxidative stress, and inflammatory pathways. We aimed to investigate the potential protective effects of IMEG against II/R injury and to explore the underlying mechanisms involved. METHODOLOGY: Thirty-two adult male Wistar albino rats were divided into four groups; sham group, IMEG group, intestinal I/R group, IMEG + Intestinal I/R group. Oxidative stress markers [malondialdehyde (MDA), reduced glutathione (GSH)], and histopathological changes were assessed. Biochemical analyses included measurement of phosphorylated AMP-activated protein kinase (p-AMPK), NOD-like receptor protein 3 (NLRP3) and caspase-3. Also, gene expression of interleukin (IL)-1β, caspase-1, apoptotic Bcl-2-associated protein x (BAX) and anti-apoptotic B-cell leukemia/lymphoma 2 protein (Bcl-2) were measured. Nuclear factor-κB (NF-κB) immuno expression was estimated.
resultsMDA, NLRP3, caspase-3 levels, IL-1β, caspase-1, Bax gene expression, and NF-κB immunohistochemical expression were all significantly elevated in the intestinal I/R group while GSH, p-AMPK levels and Bcl-2 gene expression were significantly decreased. Every metric indicated a notable improvement with IMEG.
conclusionIMEG exerts a protective effect against intestinal I/R injury through its antioxidant, anti-inflammatory, and anti-apoptotic properties (Fig. 1).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.